https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

OLC Demonstrates Safety and Tolerability in Patients With CKD and Hyperphosphatemia

OLC Demonstrates Safety and Tolerability in Patients With CKD and Hyperphosphatemia

A phase 2 trial shows oxylanthanum carbonate (OLC) effectively manages hyperphosphatemia in patients with chronic kidney disease (CKD), offering a promising treatment option.

administrator

Related Articles